Can-fite Biopharma Ltd. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Loading chart…
Third-party market data · may be delayed
Under review: data-quality checks not passed.
Under review: data-quality checks not passed. We'll show the comparison once resolved.
Can-fite Biopharma Ltd. valuation: adjust assumptions and compare models →
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
Can-fite Biopharma has little or no product revenue yet; it used $9m of cash in the twelve months. The diluted share count is up 127.0% on a year earlier, which dilutes existing holders. It passes 1 of our 2 financial-health checks.
Our model value for Can-fite Biopharma is under review, so past values are not shown until it is resolved.
Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.
Can-fite Biopharma Ltd.'s trailing-twelve-month revenue fell 39.9% year on year, with a free-cash-flow margin of -2210.1%.
Current signal Revenue growth decelerating: TTM revenue growth slowed to -39.9% (-30.6pp vs the prior quarter), the 4th consecutive quarterly slowdown.
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Loading chart…
Third-party market data · may be delayed
Company announcements, filed results and changes that matter to shareholders.
No recent updates are available for CANF from the sources we follow. See filings →
The inputs used by the models below have passed source checks. Individual model values are available below and in the interactive valuator. Their differences are shown explicitly; the platform combined value and recommendation remain withheld.
We value Can-fite Biopharma Ltd. as an operating company, with every model that fits that kind of business. Cost of equity 9.8%: the 10-year Treasury yield (4.9%) plus a beta of 1.08 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: This model is withheld pending its input or assumption review. |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | ~$0.4 ~$0.8–$2.9 | Included, half weight |
| Combined value Individual source-checked model scenarios are available. The platform combined value and recommendation remain withheld. | — | Combined value withheld. Review the individual models and their assumptions. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Can-fite Biopharma Ltd. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
| At fiscal year end | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Share price | $3780.00 | $660.00 | $356.00 | $258.00 | $122.00 | $44.00 | $32.60 | $4.00 |
| Market value | $294.1bn | $113.4bn | $63.8bn | $71.3bn | $49.8bn | $9m | $12m | $3m |
| + Net debt (− = net cash) | −$4m | −$3m | −$8m | −$4m | −$3m | −$4m | −$5m | −$6m |
| Enterprise value | $294.1bn | $113.4bn | $63.8bn | $71.3bn | $49.8bn | $5m | $7m | −$2m |
| Multiples | ||||||||
| Price / sales | n/m | n/m | n/m | n/m | n/m | 12.6x | 17.5x | 8.1x |
| Price / earnings | — | — | — | — | — | — | — | — |
| Price / free cash flow | — | — | — | — | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — |
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | — | — | $404000 | −0% |
| Next | — | — | $404000 | 0% |
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| CANF | −28% | −53% | −64% | −26% | −88% | −59% |
| Industry peers (median) | −36% | −57% | −17% | −29% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| CANF | 42% | 42% | 25% | 58% | 8% | 64% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| CANF | −66% | −59% | −75% | −70% | −92% | −73% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 2, 2015: 100% from December 1, 2015 to October 30, 2026. Getting back needed a 657307% gain, and the shares have not yet recovered.
Source: SEC EDGAR filings. Retrieved Invalid Date.
| Period | Revenue (TTM) |
|---|---|
| FY18 Q4 | $3.8M |
| FY19 Q4 | $2M |
| FY20 Q4 | $763K |
| FY21 Q4 | $853K |
| FY22 Q4 | $810K |
| FY23 Q4 | $743K |
| FY24 Q4 | $674K |
| FY25 Q4 | $405K |
Source: SEC EDGAR filings. Retrieved Invalid Date.
| Period | Revenue growth, TTM YoY |
|---|---|
| FY19 Q4 | -46.8% |
| FY20 Q4 | -62.5% |
| FY21 Q4 | 11.8% |
| FY22 Q4 | -5.0% |
| FY23 Q4 | -8.3% |
| FY24 Q4 | -9.3% |
| FY25 Q4 | -39.9% |
Source: SEC EDGAR filings. Retrieved Invalid Date.
| Period | Operating margin (TTM) |
|---|---|
| FY18 Q4 | -141.7% |
| FY19 Q4 | -590.9% |
| FY20 Q4 | -1853.1% |
| FY21 Q4 | -1505.5% |
| FY22 Q4 | -1246.4% |
| FY23 Q4 | -1103.0% |
| FY24 Q4 | -1206.2% |
| FY25 Q4 | -2456.8% |
Source: SEC EDGAR filings. Retrieved Invalid Date.
| Period | FCF margin (TTM) |
|---|---|
| FY18 Q4 | -109.6% |
| FY19 Q4 | -545.6% |
| FY20 Q4 | -1584.4% |
| FY21 Q4 | -1157.0% |
| FY22 Q4 | -1334.6% |
| FY23 Q4 | -1136.2% |
| FY24 Q4 | -1133.8% |
| FY25 Q4 | -2210.1% |
| Fiscal year | 2018 Dec 2018 | 2019 Dec 2019 | 2020 Dec 2020 | 2021 Dec 2021 | 2022 Dec 2022 | 2023 Dec 2023 | 2024 Dec 2024 | 2025 Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| Revenue | 4 | 2 | 1 | 1 | 1 | 1 | 1 | 0 |
| EBITDA | −5 | −12 | −14 | −13 | −10 | −8 | −8 | −10 |
| Operating income | −5 | −12 | −14 | −13 | −10 | −8 | −8 | −10 |
| Net income | −7 | −13 | −14 | −13 | −10 | −8 | −8 | −10 |
| Diluted EPS | −$0.09 | −$0.07 | −$0.08 | — | — | −$35.84 | −$21.72 | −$11.94 |
| Growth (year on year) | ||||||||
| Revenue | — | −46.8% | −62.5% | +11.8% | −5.0% | −8.3% | −9.3% | −39.9% |
| Margins | ||||||||
| EBITDA margin | −141.4% | −590.2% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Operating margin | −141.7% | −590.9% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Net margin | −172.0% | −621.3% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Free-cash-flow margin | −109.6% | −545.6% | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% |
| Cash flow | ||||||||
| Cash from operations | −4 | −11 | −12 | −10 | −11 | −8 | −8 | −9 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −4 | −11 | −12 | −10 | −11 | −8 | −8 | −9 |
| Stock-based pay | — | — | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow after stock pay | — | — | −12 | −10 | −11 | −9 | −8 | −9 |
| Balance sheet | ||||||||
| Cash | 4 | 3 | 8 | 4 | 3 | 4 | 5 | 6 |
| Total debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net debt (negative = net cash) | −4 | −3 | −8 | −4 | −3 | −4 | −5 | −6 |
| Diluted shares | 78m | 172m | 179m | 277m | 408m | — | — | — |
| Returned to shareholders | ||||||||
| Dividends | — | — | 1 | 3 | — | — | — | — |
| Total returned | — | — | 1 | 3 | — | — | — | — |
| Last 12 months unless stated | CANF | CRVO | CRDF | CLNN | MNOV | STTK | Median |
|---|---|---|---|---|---|---|---|
| Revenue, last 12 months | $405000 | $331295 | $508000 | $197000 | $920481 | $1m | $55m |
| Revenue growth, last 12 months | −39.9% | −95.7% | −7.0% | −31.1% | 875.7% | −66.6% | 12.2% |
| Revenue growth, 3-year average | — | −52.7% | 7.2% | −36.9% | — | 5.2% | 13.7% |
| Revenue growth, latest quarter | — | −100.0% | −14.0% | 233.3% | 240.6% | −66.6% | 10.2% |
| Gross margin | — | 100.0% | 100.0% | 70.1% | 100.0% | — | 82.9% |
| Operating margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −191.1% |
| Operating margin, 3-year average | — | <−999% | <−999% | <−999% | −905.8% | <−999% | −363.5% |
| Net margin | <−999% | <−999% | <−999% | <−999% | <−999% | <−999% | −172.8% |
| Cash from operations / revenue | <−999% | <−999% | <−999% | <−999% | −989.7% | <−999% | −168.8% |
| Free-cash-flow margin | <−999% | — | <−999% | <−999% | −991.2% | <−999% | −168.1% |
| Free-cash-flow margin, 3-year average | — | — | <−999% | <−999% | <−999% | <−999% | −310.0% |
| Stock pay / revenue | 84.0% | 393.0% | >999% | >999% | 100.3% | 853.2% | 20.7% |
| Change in share count | 127.0% | 8.4% | 15.8% | 35.4% | 0.2% | 15.3% | 8.3% |
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Citadel Advisors LLC | $96,623 | 33K | 64.8% | ▼ 4.7% |
| Rhumbline Advisers | $51,771 | 17K | 34.7% | ▼ 16.6% |
| Fifth Third Bancorp | $446 | 0K | 0.3% | 0.0% |
| Wells Fargo & Company | $175 | 0K | 0.1% | ▼ 52.8% |
| Activest Wealth Management | $30 | 0K | 0.0% | 0.0% |
| TD Waterhouse Canada Inc. | $4 | 0K | 0.0% | 0.0% |
| Morgan Stanley | $3 | 0K | 0.0% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Can-fite Biopharma Ltd.'s complete shareholder register. Values are as reported by the filers .
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
New research on the companies we cover arrives in the weekly email. Free, one email a week.
